Flowvium

Pembanding Perusahaan

Analisis berdampingan posisi rantai pasokan, sinyal institusional, dan skor kesenjangan berita.

VS

Tingkat Kapitalisasi Pasar

MegavsMega

Peran Rantai

leadervsleader

Skor Kesenjangan

N/AvsN/A

Aktivitas IB

N/AvsN/A

Perbandingan bauran pendapatan

LLY
NVO
LLY

Eli Lilly and Company

LLY · pharma-biotech

leaderMega ($100B+)
Profil lengkap

Tentang

Eli Lilly is the world's most valuable pharmaceutical company, propelled by the blockbuster GLP-1 receptor agonist tirzepatide (Mounjaro/Zepbound) for diabetes and obesity. Its Alzheimer's antibody donanemab and strong oncology pipeline give it one of the most promising drug portfolios in the industry.

Didirikan

1876

Karyawan

43,000+

Kantor Pusat

Indianapolis, Indiana, USA

Pendapatan

$52.8B

Diabetes & Obesity52%
Oncology18%
Immunology12%
Neuroscience10%
Other (Insulin Legacy)8%

Sinyal kesenjangan berita

Tidak ada data kesenjangan berita untuk ticker ini.

Sinyal institusional

Tidak ada sinyal 13F yang tercatat untuk ticker ini.

Hubungan kunci

NVO· Novo Nordisk
competitor
PFE· Pfizer Inc.
competitor
REGN· Regeneron Pharmaceuticals
competitor
MRNA· Moderna, Inc.
partner
NVO

Novo Nordisk

NVO · pharma-biotech

leaderMega ($100B+)
Profil lengkap

Tentang

Novo Nordisk is the global leader in diabetes care and has become a GLP-1 giant with Ozempic and Wegovy. The obesity-drug revolution has made it Europe's most valuable company. Its near-monopoly on injectable semaglutide positions it at the center of the $100B+ weight-loss drug market.

Didirikan

1923

Karyawan

64,000+

Kantor Pusat

Bagsvaerd, Denmark

Pendapatan

$42.6B

GLP-1 Diabetes (Ozempic, Rybelsus)42%
Obesity (Wegovy)25%
Insulin20%
Rare Disease & Other13%

Sinyal kesenjangan berita

Tidak ada data kesenjangan berita untuk ticker ini.

Sinyal institusional

Tidak ada sinyal 13F yang tercatat untuk ticker ini.

Hubungan kunci

LLY· Eli Lilly and Company
competitor
PFE· Pfizer Inc.
competitor